SEC Comment Letter for ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525) (AZR) — Mar 28, 2019
ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525)
Date: March 28, 2019 · CIK: 0001513525 · Accession: 0000000000-19-006089
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-230470
Letter
March 28, 2019 William B. Stilley, III President and Chief Executive Officer Adial Pharmaceuticals, Inc. 1001 Research Park Blvd., Suite 100 Charlottesville, VA 22911 Re:Adial Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed March 22, 2019 File No. 333-230470 Dear Mr. Stilley: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Leslie Marlow, Esq.
Show Raw Text
March 28, 2019
William B. Stilley, III
President and Chief Executive Officer
Adial Pharmaceuticals, Inc.
1001 Research Park Blvd., Suite 100
Charlottesville, VA 22911
Re:Adial Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed March 22, 2019
File No. 333-230470
Dear Mr. Stilley:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Leslie Marlow, Esq.